MedDataX Logo

Gonadal Function in Thalassemic Patient

NCT ID: NCT07288762

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-07

Study Completion Date

2026-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patient with transfusion depandant beta thalassemia with accumulation of iron in their body affect pituitary gland and gonades lead to impaired their functions .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

detection of any abnormalities in pituitary gland hormones ( FSH , LH , serum prolactin ) gonadal hormones ( serum testesterone , antimullerian hormone , INSL3 , inhibin B hormone )

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thalassemia Majors (Beta-Thalassemia Major)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

INSL3 or inhibin B hormone in transfusion depandant beta thalassemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1 transfusion depandant beta thalassemia

transfusion depandant beta thalassemia 10 - 18 years old age gonadal function assesment

serum inhibin B serum INSL3 serum AMH

Intervention Type DIAGNOSTIC_TEST

transfusion depandant beta thalassemia with measure gonadal function serum INSL3 serum inhibin B serum AMH

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum inhibin B serum INSL3 serum AMH

transfusion depandant beta thalassemia with measure gonadal function serum INSL3 serum inhibin B serum AMH

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* transfusion depandant beta thalassemia
* age 10 to 18 year old age

Exclusion Criteria

* age below 10 year old age or above 18 year old age
* associated with another disease
Minimum Eligible Age

10 Years

Maximum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hager Saadeldin Mohamed

pediatric resident

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

hager Saadeldin, resident

Role: PRINCIPAL_INVESTIGATOR

Sohag University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hager Saadeldin saadeldin, pediatric resident

Role: CONTACT

Phone: +201065099621

Email: [email protected]

Ahmed Ahmed Moniur Hegab, Doctor

Role: CONTACT

Phone: +201158744246

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-25-9-18MS

Identifier Type: -

Identifier Source: org_study_id